Kanková-Vancurová M, Jílek P, Fisterle V, Procházková J
Pharmaceutical Faculty, Charles University, Hradec Králové, Czechoslovakia.
Acta Virol. 1992 May;36(3):284-92.
The toxicity of acyclovir (ACV) produced by Lachema, Brno was compared with that of Zovirax, Wellcome. The in vitro suppressive effect of both substances was found equal and concentration dependent. The primary humoral antibody response was more sensitive to ACV than the cellular (blast transformation) response. However, spleen cells of drug-treated mice (either with the domestic compounds or Wellcome origin) differed neither in blast transformation test nor in the secretory antibody response. None of the drugs when given in adequate therapeutic dose did significantly influence the cell mediated response or antibody formation by spleen cells. Summing up, the acute immunotoxicity of both compounds was low; in this respect acyclovir Lachema did not differ from Zovirax Wellcome.
将布尔诺拉赫马公司生产的阿昔洛韦(ACV)的毒性与威康公司的无环鸟苷的毒性进行了比较。发现两种物质的体外抑制作用相同且呈浓度依赖性。初次体液抗体反应比细胞(母细胞转化)反应对ACV更敏感。然而,用药物处理过的小鼠(无论是使用国产化合物还是威康公司的产品)的脾细胞在母细胞转化试验和分泌抗体反应中均无差异。当给予足够的治疗剂量时,两种药物均未对脾细胞的细胞介导反应或抗体形成产生显著影响。总之,两种化合物的急性免疫毒性都很低;在这方面,拉赫马公司的阿昔洛韦与威康公司的无环鸟苷没有区别。